FI890776A - Diagnos, bedoemning och terapi av kranskaerlssjukdom genom belastningssimulering genom administrering av en belastningssimulerande betaantagonist i ett slutet system. - Google Patents

Diagnos, bedoemning och terapi av kranskaerlssjukdom genom belastningssimulering genom administrering av en belastningssimulerande betaantagonist i ett slutet system. Download PDF

Info

Publication number
FI890776A
FI890776A FI890776A FI890776A FI890776A FI 890776 A FI890776 A FI 890776A FI 890776 A FI890776 A FI 890776A FI 890776 A FI890776 A FI 890776A FI 890776 A FI890776 A FI 890776A
Authority
FI
Finland
Prior art keywords
genom
responses
diagnosis
terapi
kranskaerlssjukdom
Prior art date
Application number
FI890776A
Other languages
English (en)
Other versions
FI890776A0 (fi
Inventor
Ronald Ralph Tuttle
Iii Clinton Eugene Browne
Original Assignee
Gensia Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensia Pharma filed Critical Gensia Pharma
Publication of FI890776A0 publication Critical patent/FI890776A0/fi
Publication of FI890776A publication Critical patent/FI890776A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C07C45/305—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation with halogenochromate reagents, e.g. pyridinium chlorochromate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00—Surgery
    • Y10S128/13—Infusion monitoring
FI890776A 1988-02-19 1989-02-17 Diagnos, bedoemning och terapi av kranskaerlssjukdom genom belastningssimulering genom administrering av en belastningssimulerande betaantagonist i ett slutet system. FI890776A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15787588A 1988-02-19 1988-02-19
US07/308,683 US5108363A (en) 1988-02-19 1989-02-09 Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist

Publications (2)

Publication Number Publication Date
FI890776A0 FI890776A0 (fi) 1989-02-17
FI890776A true FI890776A (fi) 1989-08-20

Family

ID=26854551

Family Applications (1)

Application Number Title Priority Date Filing Date
FI890776A FI890776A (fi) 1988-02-19 1989-02-17 Diagnos, bedoemning och terapi av kranskaerlssjukdom genom belastningssimulering genom administrering av en belastningssimulerande betaantagonist i ett slutet system.

Country Status (13)

Country Link
US (4) US5108363A (fi)
EP (2) EP0329464B1 (fi)
JP (2) JP2806543B2 (fi)
AT (2) ATE159710T1 (fi)
AU (1) AU634152B2 (fi)
DE (2) DE68924661T2 (fi)
DK (1) DK73589A (fi)
ES (2) ES2081299T3 (fi)
FI (1) FI890776A (fi)
GR (2) GR3018764T3 (fi)
IE (2) IE71651B1 (fi)
NO (1) NO890704L (fi)
NZ (1) NZ239270A (fi)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7013175B2 (en) 2000-06-30 2006-03-14 Lifewaves International, Inc. Systems and methods for assessing and modifying an individual's physiological condition
USRE40401E1 (en) 1993-11-12 2008-06-24 Lifewaves International, Inc. Therapeutic exercise program

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6144385A (ja) * 1984-08-07 1986-03-04 Tokyu Constr Co Ltd 構造物内の放射線吸収体の探査方法
IL82997A0 (en) * 1986-07-11 1987-12-20 Tanabe Seiyaku Co Method for epimerizing an optically active benzyl alcohol derivative
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
AU629989B2 (en) * 1989-10-10 1992-10-15 Glaxo Group Limited Phenethanolamine derivatives
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5254087A (en) * 1990-01-29 1993-10-19 Ivra Systems, Inc. Tourniquet apparatus for intravenous regional anesthesia
US5607447A (en) * 1993-09-28 1997-03-04 Mcewen; James A. Physiologic tourniquet
US5556415A (en) * 1990-01-29 1996-09-17 Mcewen; James A. Physiologic tourniquet for intravenous regional anesthesia
US5281623A (en) * 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
AU3071992A (en) * 1991-11-13 1993-06-15 Gensia, Inc. Methods for increasing the sensitivity and decreasing the side effects of pharmacological stress testing for coronary artery disease
IL104365A0 (en) * 1992-01-31 1993-05-13 Gensia Pharma Method and apparatus for closed loop drug delivery
HUT64459A (en) * 1992-03-31 1994-01-28 Richter Gedeon Vegyeszet Process and apparatus for the diagnostics of cardiovascular
US5840026A (en) * 1994-09-21 1998-11-24 Medrad, Inc. Patient specific dosing contrast delivery systems and methods
US6397098B1 (en) * 1994-09-21 2002-05-28 Medrad, Inc. Data communication and control for medical imaging systems
US5551953A (en) * 1994-10-31 1996-09-03 Alza Corporation Electrotransport system with remote telemetry link
US7204848B1 (en) 1995-03-01 2007-04-17 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
US5775329A (en) * 1995-06-07 1998-07-07 Gensia, Inc. Method and compounds for diagnosing coronary artery disease
US5855589A (en) * 1995-08-25 1999-01-05 Mcewen; James A. Physiologic tourniquet for intravenous regional anesthesia
US5931853A (en) * 1995-08-25 1999-08-03 Mcewen; James A. Physiologic tourniquet with safety circuit
US6430997B1 (en) * 1995-11-06 2002-08-13 Trazer Technologies, Inc. System and method for tracking and assessing movement skills in multidimensional space
DE69614146T2 (de) * 1995-12-22 2002-04-11 Abbott Lab Verfahren zur herstellung von alkyl oder aryl aldehydzwischenprodukten
US5874601A (en) * 1996-03-14 1999-02-23 Abbott Laboratories Process of protecting a 1,2-aminoalcohol for reductive amination coupling
US5706822A (en) * 1996-03-29 1998-01-13 Kozz Incorporated Method and computer program for creating individualized exercise protocols
US5711316A (en) * 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US5713923A (en) * 1996-05-13 1998-02-03 Medtronic, Inc. Techniques for treating epilepsy by brain stimulation and drug infusion
WO1998024753A1 (fr) * 1996-12-02 1998-06-11 Chisso Corporation Derives de nitro-alcool actifs optiquement, derives d'amino-alcool actifs optiquement et leur procede de preparation
US6018679A (en) * 1997-01-29 2000-01-25 Novartis Finance Corp. Iontophoretic transdermal delivery and control of adverse side-effects
MXPA00011835A (es) * 1998-06-03 2002-10-17 Scott Lab Inc Aparato y metodo para proveer alivio del dolor de un paciente consciente y ansiedad asociada con procedimientos medicos o quirurgicos.
AU761522B2 (en) * 1998-07-13 2003-06-05 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
EP1121141A2 (en) * 1998-10-13 2001-08-08 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US6361522B1 (en) * 1999-10-21 2002-03-26 Cardiac Pacemakers, Inc. Drug delivery system for implantable cardiac device
US10353856B2 (en) 2011-03-17 2019-07-16 Carefusion 303, Inc. Scalable communication system
US9741001B2 (en) 2000-05-18 2017-08-22 Carefusion 303, Inc. Predictive medication safety
US9069887B2 (en) * 2000-05-18 2015-06-30 Carefusion 303, Inc. Patient-specific medication management system
US9427520B2 (en) 2005-02-11 2016-08-30 Carefusion 303, Inc. Management of pending medication orders
CZ20023818A3 (cs) 2000-05-18 2003-06-18 Alaris Meidical Systems, Inc. Systém a způsob pro správu informací týkajících se poskytování lékařské péče
US10062457B2 (en) 2012-07-26 2018-08-28 Carefusion 303, Inc. Predictive notifications for adverse patient events
US11087873B2 (en) 2000-05-18 2021-08-10 Carefusion 303, Inc. Context-aware healthcare notification system
US7860583B2 (en) 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
US7369890B2 (en) 2000-11-02 2008-05-06 Cardiac Pacemakers, Inc. Technique for discriminating between coordinated and uncoordinated cardiac rhythms
US6689117B2 (en) 2000-12-18 2004-02-10 Cardiac Pacemakers, Inc. Drug delivery system for implantable medical device
US7493162B2 (en) * 2001-06-15 2009-02-17 Cardiac Pacemakers, Inc. Pulmonary vein stent for treating atrial fibrillation
US7209783B2 (en) * 2001-06-15 2007-04-24 Cardiac Pacemakers, Inc. Ablation stent for treating atrial fibrillation
US7340303B2 (en) 2001-09-25 2008-03-04 Cardiac Pacemakers, Inc. Evoked response sensing for ischemia detection
WO2003038566A2 (en) * 2001-11-01 2003-05-08 Scott Laboratories, Inc. User interface for sedation and analgesia delivery systems and methods
US20030140928A1 (en) * 2002-01-29 2003-07-31 Tuan Bui Medical treatment verification system and method
US10173008B2 (en) 2002-01-29 2019-01-08 Baxter International Inc. System and method for communicating with a dialysis machine through a network
US8775196B2 (en) 2002-01-29 2014-07-08 Baxter International Inc. System and method for notification and escalation of medical data
US7236821B2 (en) * 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
JP2005530736A (ja) * 2002-04-18 2005-10-13 シーブイ・セラピューティクス・インコーポレイテッド ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法
US20040172301A1 (en) * 2002-04-30 2004-09-02 Mihai Dan M. Remote multi-purpose user interface for a healthcare system
US20050065817A1 (en) * 2002-04-30 2005-03-24 Mihai Dan M. Separation of validated information and functions in a healthcare system
US20040176667A1 (en) * 2002-04-30 2004-09-09 Mihai Dan M. Method and system for medical device connectivity
US8234128B2 (en) 2002-04-30 2012-07-31 Baxter International, Inc. System and method for verifying medical device operational parameters
US20040172300A1 (en) * 2002-04-30 2004-09-02 Mihai Dan M. Method and system for integrating data flows
US20040167804A1 (en) * 2002-04-30 2004-08-26 Simpson Thomas L.C. Medical data communication notification and messaging system and method
US20040039055A1 (en) * 2002-06-20 2004-02-26 Lopaschuk Gary D. Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs
US7089055B2 (en) * 2002-06-28 2006-08-08 Cardiac Pacemakers, Inc. Method and apparatus for delivering pre-shock defibrillation therapy
AU2003275460A1 (en) * 2002-10-03 2004-04-23 Scott Laboratories, Inc. Systems and methods for providing trend analysis in a sedation and analgesia system
EP1556834A4 (en) 2002-10-03 2009-04-01 Scott Lab Inc SYSTEMS AND METHOD FOR PROVIDING SENSOR FUSION
US7072711B2 (en) 2002-11-12 2006-07-04 Cardiac Pacemakers, Inc. Implantable device for delivering cardiac drug therapy
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7567841B2 (en) 2004-08-20 2009-07-28 Cardiac Pacemakers, Inc. Method and apparatus for delivering combined electrical and drug therapies
US8295914B2 (en) 2004-11-16 2012-10-23 Medrad, Inc. Systems and methods of determining patient transfer functions and modeling patient response to a pharmaceutical injection
DK2902053T3 (da) 2004-11-24 2017-11-13 Bayer Healthcare Llc Anordninger, systemer og fremgangsmåder til væskefremføring
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7616990B2 (en) 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US8182443B1 (en) * 2006-01-17 2012-05-22 Masimo Corporation Drug administration controller
JP2009531280A (ja) * 2006-01-25 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
DK2097835T3 (en) 2006-12-29 2018-09-03 Bayer Healthcare Llc PATIENT-BASED PARAMETER GENERATION SYSTEMS FOR MEDICAL INJECTION PROCEDURES
WO2008092257A1 (en) * 2007-01-29 2008-08-07 National Research Council Of Canada Use of catecholamines and related compounds as anti-angiogenic agents
US8428694B2 (en) 2007-07-17 2013-04-23 Medrad, Inc. Methods for determination of parameters for a procedure, for estimation of cardiopulmonary function and for fluid delivery
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US10089443B2 (en) 2012-05-15 2018-10-02 Baxter International Inc. Home medical device systems and methods for therapy prescription and tracking, servicing and inventory
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
US8554579B2 (en) 2008-10-13 2013-10-08 Fht, Inc. Management, reporting and benchmarking of medication preparation
US9421330B2 (en) * 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
CA2769030C (en) 2009-07-30 2016-05-10 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20110137297A1 (en) * 2009-09-17 2011-06-09 Kiani Massi Joe E Pharmacological management system
CA2803169C (en) 2010-06-24 2020-09-22 Medrad, Inc. Modeling of pharmaceutical propagation and parameter generation for injection protocols
DK2850418T3 (da) 2012-05-14 2019-05-20 Bayer Healthcare Llc Systemer og fremsgangsmåder til bestemmelse af protokoller for farmaceutisk væskeinjektion baseret på røntgenrørsspænding
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US8761717B1 (en) 2012-08-07 2014-06-24 Brian K. Buchheit Safety feature to disable an electronic device when a wireless implantable medical device (IMD) is proximate
SG11201501427PA (en) 2012-08-31 2015-03-30 Baxter Corp Englewood Medication requisition fulfillment system and method
CA2889210C (en) 2012-10-26 2020-12-15 Baxter Corporation Englewood Improved image acquisition for medical dose preparation system
NZ707430A (en) 2012-10-26 2016-04-29 Baxter Corp Englewood Improved work station for medical dose preparation system
US11182728B2 (en) 2013-01-30 2021-11-23 Carefusion 303, Inc. Medication workflow management
US10430554B2 (en) 2013-05-23 2019-10-01 Carefusion 303, Inc. Medication preparation queue
US9946844B2 (en) * 2013-02-22 2018-04-17 Cloud Dx, Inc. Systems and methods for monitoring patient medication adherence
AU2014241019A1 (en) 2013-03-13 2015-09-03 Carefusion 303, Inc. Patient-specific medication management system
EP2973370A4 (en) 2013-03-13 2016-08-17 Carefusion 303 Inc PREDICTIVE MEDICAMENT SAFETY
US9555379B2 (en) 2013-03-13 2017-01-31 Bayer Healthcare Llc Fluid path set with turbulent mixing chamber, backflow compensator
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2016003902A1 (en) 2014-06-30 2016-01-07 Baxter Corporation Englewood Managed medical information exchange
US11107574B2 (en) 2014-09-30 2021-08-31 Baxter Corporation Englewood Management of medication preparation with formulary management
US11575673B2 (en) 2014-09-30 2023-02-07 Baxter Corporation Englewood Central user management in a distributed healthcare information management system
AU2015358483A1 (en) 2014-12-05 2017-06-15 Baxter Corporation Englewood Dose preparation data analytics
CA2978455A1 (en) 2015-03-03 2016-09-09 Baxter Corporation Englewood Pharmacy workflow management with integrated alerts
CA2985719C (en) 2015-06-25 2024-03-26 Gambro Lundia Ab Medical device system and method having a distributed database
EP3423130A1 (en) 2016-03-03 2019-01-09 Bayer Healthcare LLC System and method for improved fluid delivery in multi-fluid injector systems
AU2017381172A1 (en) 2016-12-21 2019-06-13 Gambro Lundia Ab Medical device system including information technology infrastructure having secure cluster domain supporting external domain
CN110869071B (zh) 2017-08-31 2023-05-02 拜耳医药保健有限公司 流体注入器系统中的动态压力控制的方法
US11598664B2 (en) 2017-08-31 2023-03-07 Bayer Healthcare Llc Injector pressure calibration system and method
JP7252143B2 (ja) 2017-08-31 2023-04-04 バイエル・ヘルスケア・エルエルシー 駆動部材の位置及び流体注入器システムの機械的較正のためのシステム及び方法
WO2019046299A1 (en) 2017-08-31 2019-03-07 Bayer Healthcare Llc FLUID PATH IMPEDANCE ASSESSMENT FOR IMPROVING FLUID DISTRIBUTION PERFORMANCE
EP3675927B1 (en) 2017-08-31 2023-12-13 Bayer Healthcare LLC Fluid injector system volume compensation system and method
US11654236B2 (en) 2019-11-22 2023-05-23 Tandem Diabetes Care, Inc. Systems and methods for automated insulin delivery for diabetes therapy
US11911595B2 (en) 2020-05-18 2024-02-27 Tandem Diabetes Care, Inc. Systems and methods for automated insulin delivery response to meal announcements

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA570892A (en) * 1959-02-17 D. Moed Hendrik Method of producing substituted aralkyl-, phenyl-, alkylamines
DE1144291B (de) * 1957-11-05 1963-02-28 Philips Nv Verfahren zur Herstellung einer optisch-aktiven broncholytisch wirksamen Verbindung
US3135797A (en) * 1958-04-15 1964-06-02 Colgate Palmolive Co Aromatic amino antispasmodic compounds
US3319623A (en) * 1964-07-13 1967-05-16 Seymour B London Blood pressure monitors
US3969410A (en) * 1972-01-12 1976-07-13 Boehringer Ingelheim Gmbh 1-(2'-Alkyl-3',4'-dihydroxy-phenyl)-2-(phenylalkyl-amino)-alkanols-(1) and salts thereof
US3803320A (en) * 1968-07-24 1974-04-09 Geigy Chem Corp Control of insects,acarinae and nematodes with basically substituted 1-cyano-o-carbamoyl-formoximes
US3803230A (en) * 1969-05-30 1974-04-09 Allen & Hanburys Ltd 5-(2-((1-methyl-3-phenylpropyl)amino)ethyl)salicylamide hydrochloride
US3651806A (en) * 1969-10-24 1972-03-28 Philip I Hirshberg Method and apparatus for administering digitalizing medications
US4086272A (en) * 1970-07-18 1978-04-25 Pfizer Inc. Phenyl-alkanolamine, alkylamine and alpha-aminoalkyl ketone derivatives as heart stimulants
GB1301134A (en) * 1970-07-18 1972-12-29 Pfizer Ltd SUBSTITUTED 1-PHENYL-2-ALLYLAMINO-ALKANOLS, 1-PHENYL-2-ALLYLAMINO-ALKANES AND alpha-AMINOALKYLPHENYL KETONES
NL7112938A (fi) * 1970-09-30 1972-04-05
US3987200A (en) * 1972-04-12 1976-10-19 Eli Lilly And Company Method for increasing cardiac contractility
JPS5310582B2 (fi) * 1973-04-28 1978-04-14
FR2328456A1 (fr) * 1975-10-22 1977-05-20 Bruneau & Cie Lab Derives de phenylethanolamine, leur preparation et leur application en therapeutique
US4080966A (en) * 1976-08-12 1978-03-28 Trustees Of The University Of Pennsylvania Automated infusion apparatus for blood pressure control and method
US4078562A (en) * 1976-08-16 1978-03-14 Diana W. Friedman Infusion pump with feedback control
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
SE402569B (sv) * 1976-11-09 1978-07-10 Aga Ab Anordning vid en andningsapparat for dykare
FI791727A (fi) * 1978-06-05 1979-12-06 Ciba Geigy Ag Foerfarande foer framstaellning av n-alkylerade aminoalkoholer
EP0006735B1 (en) * 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4845127A (en) * 1978-07-03 1989-07-04 Eli Lilly And Company Phenethanolamines, compositions containing the same and method for effecting weight control
IL57673A0 (en) * 1978-07-03 1979-10-31 Lilly Co Eli Optically active phenethanolamines and method for increasing cardiac contractility
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
US4280494A (en) * 1979-06-26 1981-07-28 Cosgrove Robert J Jun System for automatic feedback-controlled administration of drugs
US4392849A (en) * 1981-07-27 1983-07-12 The Cleveland Clinic Foundation Infusion pump controller
EP0204948B1 (en) * 1983-01-31 1990-03-28 Eli Lilly And Company Growth promotion of animals with phenethanol amines
US4837305A (en) * 1983-02-03 1989-06-06 The Regents Of The University Of California Derivatives of β-adrenergic antagonists
US5135479A (en) * 1983-08-18 1992-08-04 Drug Delivery Systems, Inc. Programmable control and mounting system for transdermal drug applicator
EP0135905A3 (de) * 1983-09-29 1986-10-22 ASTA Pharma Aktiengesellschaft Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane
US4562206A (en) * 1983-12-23 1985-12-31 Key Pharmaceuticals, Inc. Orally effective inotropic compounds
US4865584A (en) * 1984-02-08 1989-09-12 Omni-Flow, Inc. Cassette for programable multiple input infusion system
CA1254091A (en) * 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US5088981A (en) * 1985-01-18 1992-02-18 Howson David C Safety enhanced device and method for effecting application of a therapeutic agent
DE3586595T2 (de) * 1985-06-10 1993-04-08 Drug Delivery Systems Inc Programmierbare kontrolle und bausystem eines verabreichungsgeraetes fuer transdermische arzneien.
US4688577A (en) * 1986-02-10 1987-08-25 Bro William J Apparatus for and method of monitoring and controlling body-function parameters during intracranial observation
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
US4931046A (en) * 1987-05-15 1990-06-05 Newman Martin H Iontophoresis drug delivery system
JPH02500339A (ja) * 1987-05-15 1990-02-08 ニューマン，マーティン・エッチ イオン浸透薬剤供給装置
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US4846792A (en) * 1988-03-08 1989-07-11 Baxter International Inc. Automatic infiltration detection system and method

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40401E1 (en) 1993-11-12 2008-06-24 Lifewaves International, Inc. Therapeutic exercise program
US7013175B2 (en) 2000-06-30 2006-03-14 Lifewaves International, Inc. Systems and methods for assessing and modifying an individual's physiological condition
US7054678B2 (en) 2000-06-30 2006-05-30 Lifewaves International, Inc. Systems and methods for assessing and modifying an individual's physiological condition
US7228168B2 (en) 2000-06-30 2007-06-05 Lifewaves International, Inc. Systems and methods for assessing and modifying an individual's physiological condition

Also Published As

Publication number Publication date
GR3018764T3 (en) 1996-04-30
JP2806543B2 (ja) 1998-09-30
EP0658538B1 (en) 1997-10-29
EP0658538A1 (en) 1995-06-21
IE960742L (en) 1989-08-19
DE68928422T2 (de) 1998-02-26
EP0329464A2 (en) 1989-08-23
DE68924661T2 (de) 1996-03-21
ATE159710T1 (de) 1997-11-15
NZ239270A (en) 1993-10-26
NO890704L (no) 1989-08-21
EP0329464A3 (en) 1991-07-17
DK73589A (da) 1989-08-20
ES2111973T3 (es) 1998-03-16
EP0329464B1 (en) 1995-11-02
ATE129644T1 (de) 1995-11-15
US5108363A (en) 1992-04-28
IE71651B1 (en) 1997-02-26
DK73589D0 (da) 1989-02-17
DE68924661D1 (de) 1995-12-07
FI890776A0 (fi) 1989-02-17
US5460605A (en) 1995-10-24
IE80716B1 (en) 1998-12-30
GR3025892T3 (en) 1998-04-30
US5395970A (en) 1995-03-07
NO890704D0 (no) 1989-02-20
DE68928422D1 (de) 1997-12-04
ES2081299T3 (es) 1996-03-01
JPH10276991A (ja) 1998-10-20
IE890526L (en) 1989-08-19
JPH0217048A (ja) 1990-01-22
US5286252A (en) 1994-02-15
AU634152B2 (en) 1993-02-18
AU3008889A (en) 1989-08-24

Similar Documents

Publication Publication Date Title
FI890776A (fi) Diagnos, bedoemning och terapi av kranskaerlssjukdom genom belastningssimulering genom administrering av en belastningssimulerande betaantagonist i ett slutet system.
Grandin Thinking in pictures, expanded edition: My life with autism
Mills Pain behaviors in infants and toddlers
Vidyasagar Possible plasticity in the rat superior colliculus
Giszter et al. Trunk sensorimotor cortex is essential for autonomous weight-supported locomotion in adult rats spinalized as P1/P2 neonates
DE69411739T2 (de) Prüfung von peripheren gefässerkrankungen
Bohdanecka et al. Amnesic effects of small bilateral brain puncture in the mouse
DE69007065T2 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
Kokkinidis Sensitization to amphetamine and tolerance to cocaine and phencyclidine stimulation in mice
Tansy et al. GI motor inhibition associated with acute exposure to methyl methacrylate vapor
Guz Does carbon dioxide excite ventilation by stimulating receptors within the lungs of mammals?
SU942748A1 (ru) Способ реабилитации бронхолегочных больных
SOLTYSIK et al. A further study on the effect of medial prefrontal ablation upon classical defensive conditioned reflexes in dogs
Paulson Techniques and procedures used to study the metabolism of pesticides in large animals
CLEARY The effect of propranolol on the training response to endurance exercise in normal human adults[Ph. D. Thesis]
Halliday et al. vi CONTENTS (PROCEEDINGS)
COOK THE EFFECT OF VARIOUS TEMPORAL ARRANGEMENTS OF PRACTICE ON THE MASTERY OF AN ANIMAL MAZE OF MODERATE
RU95101695A (ru) Тренажер ветеринарный
MIL'MAN Components and levels in functional structure of human activity
DE69104058D1 (de) N-[(2-thenoylmerkapto-3-methyl)-butanoyl]-homocysteinthiolacton, verfahren zu seiner herstellung und diese enthaltende pharmaceutische zusammensetzungen.
Spence On the Mode of Action of Strychnia
Caldwell Classical conditioning I: Its utilization in producing abnormal breathing in sheep
Kemp Oxytetracycline: a Long-Acting Formulation
SE8305679D0 (sv) Treningsanordning for benmuskulatur, cirkulation och armmuskulatur
Hurme Experiences of psychodrama courses.

Legal Events

Date Code Title Description
FA Application withdrawn

Owner name: GENSIA PHARMACEUTICALS, INC.